People · Operator
Named in public records as an officer, director or promoter · active 2013–2020 · Biotechnology, Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Taris Biomedical Inc | — | Biotechnology | Series B | $36.9M | $535.8M | 2013 |
| Faze Medicines, Inc. | — | Biotechnology | Series B | $30.4M | $999.5M | 2020 |
| Rheos Medicines, Inc. | — | Biotechnology | Series B | $27.5M | $1.1B | 2018 |
| Edimer Pharmaceuticals, Inc. | — | Pharmaceuticals | Series A | $9.8M | $303.4M | 2013 |
Cary Pfeffer at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Cary Pfeffer on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Robert Langer | 1 | 36 |
| Kevin Bitterman | 1 | 15 |
| Michael Greeley | 1 | 15 |
| David Mott | 1 | 9 |
| Robert Crane | 1 | 7 |
| Robert Tepper | 1 | 7 |
| ABBIE CELNIKER | 1 | 6 |
| Mitchell Bloom | 1 | 6 |
| Diane Marcou | 1 | 5 |
| Charles Homcy | 1 | 4 |
| Michael Cima | 1 | 4 |
| Dennis Ausiello | 1 | 4 |
| William Aliski | 1 | 4 |
| Christine Bunt | 1 | 4 |
| Ed Kania | 1 | 3 |
| Purnanand Sarma | 1 | 3 |
| Edward Kania | 1 | 2 |
| Stephen Sherwin | 1 | 2 |
| Jeffrey Bluestone | 1 | 2 |
| Dan Matloff | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.